Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2120–2122. doi: 10.1128/aac.39.9.2120

Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity.

D B Mendel 1, D B Barkhimer 1, M S Chen 1
PMCID: PMC162892  PMID: 8540727

Abstract

It has been observed that herpes simplex virus mutants with deficient or altered thymidine kinase activity are more susceptible to Cidofovir (CDV; 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate) in tissue culture than are the parental strains. During infection of cells, the elevation of the dCTP pool by thymidine kinase mutant viruses is less than that induced by the wild-type virus. The competition between CDV diphosphate and dCTP at the viral polymerase is therefore changed in favor of CDV diphosphate, enhancing its activity.

Full Text

The Full Text of this article is available as a PDF (171.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrei G., Snoeck R., Goubau P., Desmyter J., De Clercq E. Comparative activity of various compounds against clinical strains of herpes simplex virus. Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):143–151. doi: 10.1007/BF01967066. [DOI] [PubMed] [Google Scholar]
  2. Bischofberger N., Hitchcock M. J., Chen M. S., Barkhimer D. B., Cundy K. C., Kent K. M., Lacy S. A., Lee W. A., Li Z. H., Mendel D. B. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother. 1994 Oct;38(10):2387–2391. doi: 10.1128/aac.38.10.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bronson J. J., Ghazzouli I., Hitchcock M. J., Webb R. R., 2nd, Martin J. C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem. 1989 Jul;32(7):1457–1463. doi: 10.1021/jm00127a010. [DOI] [PubMed] [Google Scholar]
  4. Chen M. S., Prusoff W. H. Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus. J Biol Chem. 1978 Mar 10;253(5):1325–1327. [PubMed] [Google Scholar]
  5. Chen M. S., Suttmann R. T., Wu J. C., Prisbe E. J. Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus. J Biol Chem. 1992 Jan 5;267(1):257–260. [PubMed] [Google Scholar]
  6. Cheng Y. C., Goz B., Prusoff W. H. Deoxyribonucleotide metabolism in Herpes simplex virus infected HeLa cells. Biochim Biophys Acta. 1975 May 16;390(3):253–263. doi: 10.1016/0005-2787(75)90346-9. [DOI] [PubMed] [Google Scholar]
  7. Cohen G. H., Factor M. N., Ponce de Leon M. Inhibition of herpes simplex virus type 2 replication by thymidine. J Virol. 1974 Jul;14(1):20–25. doi: 10.1128/jvi.14.1.20-25.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crumpacker C. S., Schnipper L. E., Marlowe S. I., Kowalsky P. N., Hershey B. J., Levin M. J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982 Feb 11;306(6):343–346. doi: 10.1056/NEJM198202113060606. [DOI] [PubMed] [Google Scholar]
  9. Darby G., Field H. J., Salisbury S. A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81–83. doi: 10.1038/289081a0. [DOI] [PubMed] [Google Scholar]
  10. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987 Dec;8(5-6):261–272. doi: 10.1016/s0166-3542(87)80004-9. [DOI] [PubMed] [Google Scholar]
  11. Ellis M. N., Keller P. M., Fyfe J. A., Martin J. L., Rooney J. F., Straus S. E., Lehrman S. N., Barry D. W. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother. 1987 Jul;31(7):1117–1125. doi: 10.1128/aac.31.7.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Erlich K. S., Mills J., Chatis P., Mertz G. J., Busch D. F., Follansbee S. E., Grant R. M., Crumpacker C. S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):293–296. doi: 10.1056/NEJM198902023200506. [DOI] [PubMed] [Google Scholar]
  13. Ho H. T., Woods K. L., Bronson J. J., De Boeck H., Martin J. C., Hitchcock M. J. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol. 1992 Jan;41(1):197–202. [PubMed] [Google Scholar]
  14. Jamieson A. T., Gentry G. A., Subak-Sharpe J. H. Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. J Gen Virol. 1974 Sep;24(3):465–480. doi: 10.1099/0022-1317-24-3-465. [DOI] [PubMed] [Google Scholar]
  15. Jamieson A. T., Subak-Sharpe J. H. Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity. J Gen Virol. 1974 Sep;24(3):481–492. doi: 10.1099/0022-1317-24-3-481. [DOI] [PubMed] [Google Scholar]
  16. Kost R. G., Hill E. L., Tigges M., Straus S. E. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med. 1993 Dec 9;329(24):1777–1782. doi: 10.1056/NEJM199312093292405. [DOI] [PubMed] [Google Scholar]
  17. Lalezari J. P., Drew W. L., Glutzer E., Miner D., Safrin S., Owen W. F., Jr, Davidson J. M., Fisher P. E., Jaffe H. S. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis. 1994 Sep;170(3):570–572. doi: 10.1093/infdis/170.3.570. [DOI] [PubMed] [Google Scholar]
  18. Maudgal P. C., De Clercq E. (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis. Invest Ophthalmol Vis Sci. 1991 May;32(6):1816–1820. [PubMed] [Google Scholar]
  19. Roehm N. W., Rodgers G. H., Hatfield S. M., Glasebrook A. L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991 Sep 13;142(2):257–265. doi: 10.1016/0022-1759(91)90114-u. [DOI] [PubMed] [Google Scholar]
  20. Sherman P. A., Fyfe J. A. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 1989 Aug 1;180(2):222–226. doi: 10.1016/0003-2697(89)90420-x. [DOI] [PubMed] [Google Scholar]
  21. Sibrack C. D., Gutman L. T., Wilfert C. M., McLaren C., St Clair M. H., Keller P. M., Barry D. W. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis. 1982 Nov;146(5):673–682. doi: 10.1093/infdis/146.5.673. [DOI] [PubMed] [Google Scholar]
  22. Snoeck R., Andrei G., De Clercq E., Gerard M., Clumeck N., Tricot G., Sadzot-Delvaux C. A new topical treatment for resistant herpes simplex infections. N Engl J Med. 1993 Sep 23;329(13):968–969. doi: 10.1056/NEJM199309233291317. [DOI] [PubMed] [Google Scholar]
  23. Soike K. F., Huang J. L., Zhang J. Y., Bohm R., Hitchcock M. J., Martin J. C. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys. Antiviral Res. 1991 Jul;16(1):17–28. doi: 10.1016/0166-3542(91)90055-v. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES